Artificial intelligence continues to transform biopharma development and clinical trial operations. 10x Genomics’ acquisition of Scale Biosciences enhances single-cell sequencing capacity and strengthens patent portfolio gaming in this competitive domain. Empatica’s EmbraceMini, a compact AI-powered wearable, offers real-time biomarker monitoring approved by the FDA, optimizing decentralized clinical trials. Absci and Almirall expanded an AI collaboration to $650 million for dermatology therapeutics, exemplifying growing capital injection. These advances promise accelerated drug development, data integration, and patient monitoring.